{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.4.2.', 'Safety Analyses', 'All safety endpoints will be tabulated or plotted by treatment group and will be', 'performed on the Safety Population. Further details will be described in the RAP.', '10.4.3.', 'Other Analyses', 'Exploratory biomarker analyses will be described in the RAP.', '10.4.4.', 'Interim Analyses', 'Conducting an interim analysis or futility assessment may not be practical due to an', 'expected fast recruitment period. By the time enough data will accumulate for any', 'meaningful interim analysis to support changes to the study design, recruitment of all', 'study participants will have concluded. However, if recruitment takes a longer than', 'anticipated, an interim analysis to reassess the variability assumptions, estimate the', 'probability of success at the end of study, and confirm the directionality of the endpoints', 'may be conducted.', 'The RAP will describe the potential interim analyses in greater detail.', '51']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '11.', 'REFERENCES', 'Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD.', 'Eur Respir J. 2004;23:932-946.', 'Chapman RW, Philips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2', 'antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009; 121:55-68.', 'FDA. Guidance for Industry. Center for Drug Evaluation and Research, United States', 'Food and Drug Administration; 2009. Drug-induced liver injury: premarketing clinical', 'evaluation.', 'GlaxoSmithKline Document Number 2013N180289 ( 03 Study ID 200163. A two part,', 'phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability,', 'pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin', '(GSK1325756) in symptomatic COPD subjects with mild to moderate airflow limitation', 'at risk for exacerbations. Report Date 05-Aug-2015.', 'GlaxoSmithKline Document Number 2014N205875 00 Study ID 201682. A', 'randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and', 'clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with', 'acute, uncomplicated influenza. Report Date 21-Nov-2014.', 'GlaxoSmithKline Document Number 2015N248339 00 Study ID 201037. A single', 'centre, open-label, 5-period, cross over, randomized study in healthy elderly subjects to', 'evaluate the relative bioavailability of hydrobromide salt and free base immediate release', 'tablet formulations of danirixin in the fed state, and to evaluate the effect of food and', 'gastric acid secretion suppression on danirixin pharmacokinetics following administration', 'of hydrobromide salt tablets. Report Date 01-Jun-2016.', \"GlaxoSmithKline Document Number YM2010/00163/07. Danirixin Investigator's\", 'Brochure, Version 09. Report Date 14-Apr-2016.', 'GOLD. From the Global Strateby for the Diagnosis, Management and Prevention of', 'COPD, Global Initiative for Chronic Obstructive Lung Disease. Global Initiative for', 'Chronic Obstructive Lung Disease, Available from: http://www.copdgold.org; 2016.', 'Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni I P, et al. SCH527123,', 'a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur', 'Respir J. 2010;35:564-570.', 'Hurst JA, Vestbo J, Anzueto A, Locantore N, Mullerova, Tal-Singer R, et al.', 'Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med.', '2010;363:1128-1138.', 'Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first', 'validation of the COPD Assessment Test (CAT). Eur Respir J. 2009;34:648-654.', '52']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R et al. Tests of the', 'responsiveness of the chronic obstructive pulmonary disease (COPD) assessment test', '(CAT) following acute exacerbation and pulmonary rehabilitation. Chest. 2012;142:134-', '140.', 'Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health', \"status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev\", 'Respir Dis. 1992;145:1321-1327.', 'Lazaar AL, Sweeney LE, MacDonald AJ et al. SB-656933, a novel CXCR2 selective', 'antagnoist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation', 'in humans. Br J Clin Pharmacol. 2011;72:282-293.', 'Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology.', '2016;21:14-23.', 'Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002', 'to 2030. PLoS Med. 2006;3:e442.', 'Meguro M, Barley EA, Spencer S et al. Development and validation of an improved', 'COPD-specific version of the St. George Respiratory Questionnaire. Chest.', '2007;132:456-463.', 'Miller B, Tal-Singer R, Lazaar A, Leidy N, Watz H, Collins D, et al. Assessing', 'symptoms in COPD: use of the E-RS daily digital diary in early drug development. Eur', 'Respir J.2016;48(S60):PA1047.', 'Nagai, K., Makita, H., Suzuki, M., Shimizu, K., Konno, S., Ito, Y. M., & Nishimura, M.', 'Differential changes in quality of life components over 5 years in chronic obstructive', 'pulmonary disease patients. International Journal of Chronic Obstructive Pulmonary', 'Disease. 2015; 10: 745-757.', 'Nair P, Gaga M, Zervas E et al. Safety and efficacy of a CXCR2 antagnoist in patients', 'with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical', 'trial. Clin Exp Allergy. 2012;42:1097-2103', \"O'Byrne PM, Metev H, Puu M et al. Efficacy and safety of a CXCR2 antagonist,\", 'AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind,', 'placebo-controlled trial. Lancet Respir Med. 2016;4:797-806.', 'Rennard SI, Dale DC, Donohue JF et al. CXCR2 antagonist MK-7123 - a phase 2 proof-', 'of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med.', '2015;191:1001-1011.', 'Vastava S, Thakur D, Sharma S, Punekar YS. Systematic review of humanistic and', 'economic burden of symptomatic chronic obstructive pulmonary disease. Pharmacoecon.', '2015;33:467-488.', '53']\n\n###\n\n", "completion": "END"}